KTOV - Kitov: Consensi Commercial Update Supports Value Buy

Kitov Pharma (KTOV) recently announced that they amended their Consensi marketing and distribution agreement with Coeptis Pharmaceuticals in the United States. As a result, Kitov will receive up to $99.5M in milestone and reimbursement payments. In addition, Kitov will get double-digit royalties, with minimum payments in the next three years. The company also updated investors on the status of the launch and commercial progress. In fact, the press release mentioned that the “initial commercial batches are now in its latest phases and will soon be ready for packaging and shipping to the U.S."